

# North Central London

Rheumatoid Arthritis Advanced Therapies Prescribing Pathway

Adjustment for COVID-19

Document Revision History		
Date	Version	Comment/Changes
04.07.2019	0.1	First draft
08.08.2019	0.2	Comments from stakeholder meeting 31.07.2019. Remove dose withdrawal and tapering section. Add information regarding tocilizumab and using other DMARDs when methotrexate contraindicated.
20.08.2019	0.3	Amendments to wording i.e. adequate response vs moderate response. Tocilizumab wording. Add references.
15.10.2019	0.4	Pathway updated for comments from stakeholders
15.11.2019	0.5	Updates added following JFC evidence review for rituximab first-, third-, fourth- and fifth line and second-line anti-TNF use in patients who are eligible for rituximab
07.01.2020	0.6	Seronegative definition added. Upadacitinib added alongside existing JAK inhibitors in preparation for expected NICE TA publication on 18 <sup>th</sup> March 2020.
28.01.2020	0.7	Prescribing algorithm updated.
07.02.2020	0.8	Upadacitinib removed following review of proposed place in therapy. Prescribing in pregnancy clarified. Section on progressing through the pathway added.
14.05.2020	0.9	COVID-19 Adjustment: removal of 5 <sup>th</sup> line. Updated references, revision history, reformatted to agreed template.

Document Details	
Document Type	Clinical Pathway
Document Name	Rheumatoid Arthritis: Advanced Therapies Prescribing Pathway Adjustment for COVID-19
Document Location	<a href="https://www.ncl-mon.nhs.uk/faq/guidelines/">https://www.ncl-mon.nhs.uk/faq/guidelines/</a>
Version	1.0
Effective From	01 June 2020
Review Date	01 January 2021
Authors	<p><b>NCL Rheumatoid Arthritis Working Group:</b>            Farhan Ismail, Commissioning and Contracting Pharmacist, NHS NEL            Farhana Shivji, Commissioning and Contracting Support Pharmacist, NHS NEL            Steven Ta, Commissioning and Contracting Support Pharmacist, NHS NEL            Professor Michael Ehrenstein, Honorary Consultant Rheumatologist, University College London Hospitals NHS Foundation Trust            Aoife Tynan, Senior Medicine Pharmacist, Royal Free London NHS Foundation Trust            Gaurang Purohit, Deputy Chief Pharmacist, Royal National Orthopaedic Hospital            Dr. Maria Leandro, Consultant Rheumatologist, University College London Hospitals NHS Foundation Trust            Colin Daff, Head of Medicines Management, Barnet CCG            Carla Reene, Prescribing Support Officer, NHS NEL</p>
Approved by (date)	<p>NCL Joint Formulary Committee (May 2020)            NCL Heads of Medicines Management (May 2020)</p>

# Contents

<b>Scope .....</b>	<b>5</b>
<b>Principles.....</b>	<b>6</b>
<b>Definitions and Lines of Therapy .....</b>	<b>6</b>
<b>Progressing through the pathway .....</b>	<b>7</b>
Biologic choice in patients unable to take methotrexate (oral and subcutaneous) .....	7
Rituximab first-line with or without methotrexate .....	8
Biologic choice in pregnancy and breastfeeding .....	8
Blueteq.....	8
<b>References.....</b>	<b>9</b>
<b>Appendix 1. Biologic Treatment Pathway .....</b>	<b>10</b>
<b>Appendix 2. Glossary.....</b>	<b>11</b>

## Scope

This document outlines the treatment pathway for adult patients with highly active rheumatoid arthritis, defined as a DAS28 score > 5.1, requiring advanced therapies: biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs). The use of conventional DMARDs (cDMARDs) is outside the scope of this pathway except where stated.

The Technology Appraisals (TAs) published by the National Institute for Health and Care Excellence (NICE) shown in Table 1 have been incorporated into this pathway.

**Table 1: NICE Technology Appraisals for Rheumatoid Arthritis**

NICE Technology Appraisal Number	Title
TA485	Sarilumab for moderate to severe rheumatoid arthritis
TA480	Tofacitinib for moderate to severe rheumatoid arthritis
TA466	Baricitinib for moderate to severe rheumatoid arthritis
TA247	Tocilizumab for the treatment of rheumatoid arthritis
TA195	Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
TA225	Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
TA415	Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)
TA375	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

## Principles

This document is based on current NICE TAs available for the management of rheumatoid arthritis, as well as local agreements which are based on clinical evidence collated by the NCL Joint Formulary Committee (JFC).

The pathway is subject to change as new evidence, NICE TAs or local agreements are released or updated that will impact on the information outlined in this document. This includes changes in drug costs that may impact on cost-effectiveness and drug choice in the treatment pathway.

Only four lines of therapy will be commissioned by CCGs under this pathway, irrespective of the modes of action for drugs previously used. 5<sup>th</sup> line treatment and beyond is not routinely commissioned and funding for such treatment will require the submission of an Individual Funding Request where clinical exceptionality can be demonstrated.

It is expected that where possible, drugs approved for use through a NICE TA are selected in preference to non-NICE approved options. It is also expected that drugs presenting best value are selected where clinically appropriate. For further prescribing information including contraindications and cautions, please refer to the relevant drug monograph in the latest version of the British National Formulary or the respective drug's Summary of Product Characteristics.

## Definitions and Lines of Therapy

The DAS28 scoring system below is used to stratify disease severity in rheumatoid arthritis.<sup>[1]</sup> The response to therapy, described by a reduction in DAS28 as defined by the European League Against Rheumatism (EULAR) is used to assess the effectiveness of treatment.

Table 2: EULAR criteria for DAS28 scores in rheumatoid arthritis<sup>[2]</sup>

Current DAS28 score	DAS28 Improvement		
	>1.2	>0.6 and ≤1.2	≤0.6
≤ 3.2	Good	Moderate	No response
>3.2 and ≤ 5.1	Moderate	Moderate	No response
>5.1	Moderate	No response	No response

Treatment response will determine whether a drug is suitable for continued use, as is stipulated by NICE in the respective TAs.

The following definitions and timelines have been agreed to describe treatment failure (non-response or loss of response) and adverse drug reactions or intolerance.

### **Primary Failure**

Patient does not demonstrate a moderate response to therapy in DAS28 (as defined by EULAR in Table 2) following 6 months of treatment.

An adverse drug reaction to a medicine within 6 months will not count as a line of therapy.

### **Secondary Failure**

Patient initially achieves a moderate response to therapy in DAS28 (as defined by EULAR in Table 2) at 6 months post-initiation, which is subsequently not sustained, resulting in failure to maintain a moderate reduction in DAS28.

An adverse drug reaction to a medicine after 6 months will count as a line of therapy.

### **Seronegative rheumatoid arthritis**

A confirmed diagnosis of rheumatoid arthritis without the presence of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies.

## **Progressing through the pathway**

The pathway is colour-coded to support the identification and thus use of the most cost-effective agents available. The expectation is that drug acquisition costs are factored into the decision-making process when selecting the most clinically appropriate drug at each line. It is anticipated that as patients move down the pathway, more expensive drugs with differing mechanisms of action will need to be selected. The rationale for using more costly agents early in the pathway will be based on clear, objective clinical situations (e.g. absolute or relative contraindications to lower-cost agents).

### **Biologic choice in patients unable to take methotrexate (oral and subcutaneous)**

Many biologic medicines used in the management of rheumatoid arthritis are licensed for use concurrently with methotrexate. It is the preferred option to use biologics in combination with methotrexate. For drugs that are off-label when used as monotherapy, these have been reviewed and approved for use by the NCL JFC. Monotherapy (off-label) has been approved for rituximab and abatacept.

In cases where patients are unable to have methotrexate, tocilizumab monotherapy is well supported, given the availability of robust evidence (ADACTA study<sup>[3]</sup>) supporting its use as monotherapy.

In circumstances where patients are intolerant or contraindicated to methotrexate, other conventional DMARDs may be used in combination with biologics. It is the responsibility of the prescriber to identify whether these combinations may be considered 'off-label' and inform patients accordingly. It is expected that patient consent is obtained and clearly documented where a medicine is being used off-label.

## Rituximab first-line with or without methotrexate

The first-line use of rituximab is off-label and does not hold a NICE approval. While it is licensed to be used with methotrexate, its use as monotherapy (i.e. without methotrexate) has been approved locally. It is expected that patient consent is obtained and clearly documented where any medicine is being used off-label.

First-line use of rituximab with or without methotrexate is approved in patients with:

- History of a demyelinating disease
- Interstitial lung disease (ILD)
- Recent history of malignancy
- Current diagnosis of malignancy
- History of lymphoma or other B cell lymphoproliferative disease
- Latent tuberculosis with a contraindication to the use of chemoprophylaxis

Any use outside of these circumstances is not routinely funded.

## Biologic choice in pregnancy and breastfeeding

Certolizumab pegol is the drug of choice in women who are confirmed pregnant as it is compatible with all three trimesters of pregnancy.<sup>[4,5]</sup> If patients are required to be switched to certolizumab pegol due to confirmation of pregnancy, whether planned or unplanned, this will not count as a line of therapy if this drug is used for a finite duration with a planned exit strategy from its use. The drug should be reviewed to stop post parturition, reverting to the most clinical- and cost-effective agent as soon as is practicable.

For certolizumab pegol prescribed pre-conception for patients planning for pregnancy, this use will count as a line of therapy on the pathway.

For further information on the use of cDMARDs or bDMARDs in pregnancy or breast feeding, please refer to the following guidance:<sup>[4]</sup>

BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids (accessed via: <https://academic.oup.com/rheumatology/article/55/9/1693/1744535>)

## Blueteq

With a view to support data-driven care, commissioners will be extracting outcomes data from Blueteq. Blueteq must therefore be used for the management of all funding requests. This includes recording treatment switches and cessation as a result of clinical review and/or remission, drug switching for patients who are confirmed or planning for pregnancy, and formulation switching during COVID-19, e.g. between intravenous and subcutaneous therapy.

Trusts are required to obtain CCG funding for the use of bDMARDs and tsDMARDs in the management of rheumatoid arthritis via Blueteq prior to starting therapy and for continuation of therapy as described on the Blueteq forms.



## References

1. European League Against Rheumatism; EULAR; 2020; Online; available from: <https://www.eular.org> [Accessed 26 May 2020]
2. Van Riel PLM; DAS28; 2020; Online; available from: <https://www.das-score.nl/das28/en/> [Accessed 26 May 2020]
3. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet* 2013; 381 (9877): 1541-1550.
4. Flint J, Panchal S, Hurrell A et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. *Rheumatology* 2016; Volume 55 (9): 1693–1697.  
Available from: <https://doi.org/10.1093/rheumatology/kev404>
5. Summary of Product Characteristics, Cimzia 200mg solution for injection in pre-filled syringe. Last updated 26 July 2019. Available from: <https://www.medicines.org.uk/emc/product/4450/smpc#PREGNANCY>

## Appendix 1. Biologic Treatment Pathway

Patients should be given one drug from each mode of action, with the exception of anti-TNFs where a maximum of 2 can be used.

<b>Green</b>	Preferred, best value medicine.	<b>Amber</b>	Not preferred, to be used when green not suitable.	<b>Red</b>	Not preferred, least cost-effective. To be used when green and amber not suitable.
--------------	---------------------------------	--------------	--	------------	--



**3rd line**

Has the patient demonstrated a moderate EULAR response (DAS28)?

No

ADA, ETA, IFX, RTX

BAR, TOF, SAR\*

TOC (SC/IV)\*, GOL, CTZ, ABT (SC/IV)

No

ADA, ETA, RTX

BAR, TOF, SAR

TOC (SC/IV)\*, ABT (SC/IV), CTZ

Has the patient suffered an ADR within six months?

Yes

No

Continue, monitor and review

Has the patient demonstrated a moderate EULAR response (DAS28)?

No

No

**4th line: Repeat 3rd line options (noting rules for ADRs within six months)**

Has the patient demonstrated a moderate EULAR response (DAS28)?

No

No

Exit biologics pathway. Submit IFR where clinical exceptionality is demonstrable

**Red font** – highlights drugs which are outside of NICE and/or are off-label at the point it is being used in the pathway. **Asterisk (\*)** – preferred choice of agent in line with NICE recommendations.

## Appendix 2. Glossary

Abbreviation	Full Term (drug class)
ABT	Abatacept (CD80/CD86 inhibitor)
ADA	Adalimumab (anti-TNF)
ADR	Adverse drug reaction
BAR	Baricitinib (JAK inhibitor)
CI	Contraindicated
CTZ	Certolizumab (anti-TNF)
DMARD	Disease modifying anti-rheumatic drug
bDMARD	Biological disease modifying anti-rheumatic drug
cDMARD	Conventional disease Modifying anti-rheumatic drug
tsDMARD	Targeted synthetic disease Modifying anti-rheumatic drug
ETA	Etanercept (anti-TNF)
GOL	Golimumab (anti-TNF)
IFX	Infliximab (anti-TNF)
MTX	Methotrexate (conventional DMARD)
RTX	Rituximab (CD20 inhibitor)
SAR	Sarilumab (IL-6 inhibitor)
TOC	Tocilizumab (IL-6 inhibitor)
TOF	Tofacitinib (JAK inhibitor)